Novavax appoints Jim Kelly as CFO and Nasir Egal as SVP of Quality Assurance

NOVAVAX INC

Jim Kelly appointed EVP, CFO and Treasurer effective August 16, 2021; John Trizzino returns to CCO/CBO role.
Kelly previously CFO at Supernus Pharmaceuticals and Vanda Pharmaceuticals; 25+ years industry experience.
Kelly receives $490k base salary, 45% target bonus, $100k signing bonus (pro-rated if leaves within 24 months), plus stock awards and severance terms.
Nasir Egal appointed SVP of Quality Assurance; former Head of Global Quality External Affairs at Sanofi and FDA research scientist.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James P. Kelly

Executive Vice President, Chief Financial Officer and Treasurer

NVAX · NOVAVAX INC

Effective: 2021-08-16
Filed: August 18, 2021, 7:59 PM ET

announced the appointment of James P. Kelly, age 55, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective August 16, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James P. Kelly was appointed as Executive Vice President, Chief Financial Officer and Treasurer at NOVAVAX INC.

Action: appointed
Role: Executive Vice President, Chief Financial Officer and Treasurer

Exact text from the filing

announced the appointment of James P. Kelly, age 55, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective August 16, 2021.

View on SEC.gov

NOVAVAX INC filing history →

Source: SEC EDGAR

accession 0001104659-21-107375

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.